GSK:NYSE
GSK plc
50,19 USD
arrow_downward
-0,83%(-0,42) 1D
50,54 USD
arrow_upward
+0,70% (+0,35)bedtimeAfter hours
Closed: 12-ноя., 16:00:02 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GSK...
Open
50,97 USD
High
51,07 USD
Low
50,45 USD
Mkt. cap
101,01 млд
Avg. vol.
5,24 млн
Volume
2,55 млн
Dividend
3,66%
Quarterly dividend
0,46 USD
Ex-dividend date
2026-ж., 12-ноя.
P/E ratio
17,69
52-wk high
61,70 USD
52-wk low
45,80 USD
EPS
2,84 USD
Beta
0,20
Shares outstanding
2,02 млд
No. of employees
67 миң
Open
50,97 USD
High
51,07 USD
Low
50,45 USD
Mkt. cap
101,01 млд
Avg. vol.
5,24 млн
Volume
2,55 млн
Dividend
3,66%
Quarterly dividend
0,46 USD
Ex-dividend date
2026-ж., 12-ноя.
P/E ratio
17,69
52-wk high
61,70 USD
52-wk low
45,80 USD
EPS
2,84 USD
Beta
0,20
Shares outstanding
2,02 млд
No. of employees
67 миң
News stories
From web sources and news partners
Zacks
·
14 саат мурун
Can Gilead Sciences' HIV Business Fuel Sustainable Long-Term Growth?
Traders Union
·
23 саат мурун
Why is GSK stock up 1.6% today?
Traders Union
·
1 күн мурун
What's behind GSK's latest 1.5% stock pullback?
Reuters
·
1 апта мурун
HP picks GSK restructuring veteran Walmsley as CEO, shares jump over 6%
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About GSK plc
CEOEmma Walmsley | Emma Walmsley
Employees66,8 миң
Founded2000-ж., 27-дек.
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websitegsk.com